| abstract |
(57) [Summary]nA method for treating prostate conditions such as prostate cancer and prostatic hypertrophy by administering 1α-hydroxyprevitamin D or active vitamin D or a combination thereof in a sustained release dosage form or a slow release sustained release formulation. Both sustained release and slow release sustained release dosage forms deliver elevated blood active vitamin D levels without the significant risk of hypercalcemia associated with other oral vitamin D preparations And provide beneficial effects on affected prostate tissue. |